drugset
drugset / Trial / NCT00696423

Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children

NCT00696423 ↗

Phase 3 Completed 467 enrolled GlaxoSmithKline
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00412854). This Phase IIIB study will compare GSK Biologicals' DTPa/Hib vaccine to separately administered DTPa and Hib vaccines in Chinese children 18 to 24 months of age, in terms of safety and immunogenicity.

Timeline

Start
2008-06-07
Primary completion
2008-07-26
Completion
2008-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Adacel Vaccine — Intramuscular
Subject HAEMOPHILUS INFLUENZAE TYPE B STRAIN 20752 CAPSULAR POLYSACCHARIDE TETANUS TOXOID CONJUGATE ANTIGEN Vaccine — Intramuscular

Indications

diphtheria tetanus